FDA Approval for Technetium Tc 99m Tilmanocept Expanded to Include Pediatric Patients


Technetium Tc 99m tilmanocept may now be used to enhance identification of lymph nodes in pediatric patients with certain tumors.

The radiopharmaceutical diagnostic agent technetium Tc 99m tilmanocept (Lymphoseek) was granted approval by the FDA for the identification of lymph nodes in pediatric patients with melanoma, rhabdomyosarcoma (RMS), and other solid tumors, according to the company responsible for the agent, Cardinal Health.

The agent now allows for clinicians to accurately enhance lymphatic mapping and sentinel lymph node biopsy in adult and pediatric patients 1 month or older with melanoma, rhabdomyosarcoma (RMS), and other solid tumors.

“This new indication opens the door for physicians, oncologists and nuclear medicine specialists to more accurately stage the spread of disease using lymphatic mapping in pediatric cancer patients,” Tiffany Olson, President of Nuclear & Precision Health Solutions at Cardinal Health, said in a press release. “Ultimately, this may help more families to be able to get answers to some of their most concerning questions.”

The use of technetium Tc 99m tilmanocept for this indication is considered safe, with less than 1% of patients experiencing injection site reaction and/or pain on clinical trials. No serious adverse effects of therapy have been reported with the agent.

In a study of pediatric patients with melanoma, RMS, and other solid tumors (n = 23), lymphatic mapping was performed 15 minutes following technetium Tc 99m tilmanocept injection. The overall rate of lymph node detection, defined as at least 1 lymph node per patients, was 96%. The average number of lymph nodes detected per patient was 3. Of the 79 nodes in 21 patients who also received dye for detection, all 47 nodes identified using blue dye were also identified with technetium Tc 99m tilmanocept.

The agent is also approved for guiding sentinel lymph node biopsy in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.


1. Cardinal Health Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK Pediatric Indication. News release. Cardinal Health. June 10, 2021. Accessed June 10, 2021. https://bit.ly/35bt1Rg

2. Lymphoseek [presciribing information]. 2013. Cardinal Health. Accessed June 10, 2021. https://bit.ly/3w7WY0x

Related Videos
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.